Infectious disease
Only a week after Pfizer and BioNTech’s preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, Moderna reported interim efficacy data for its vaccine of 94.5%.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here’s a look.
Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.
There have been some concerns over the accuracy of COVID-19 rapid antigen tests—the clinical diagnostic tests that evaluate for active infections by testing for the presence of the virus’s antigens.
A recent study found that Vitamin D deficiency may be associated with an increased COVID-19 risk.
Despite the greenlight from the U.S. Food and Drug Administration as an emergency treatment, there are some questions about how effective the treatment will actually prove to be due to labeling limitations.
A group of Researchers in St. Louis published the results of a clinical trial evaluating antidepressant fluvoxamine, for early treatment for COVID-19.
Integrating digital tools for manufacturing process development, control and data analytics brings data together in ways that enhance visibility system-wide.
Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.
PRESS RELEASES